Side-by-side · Research reference
5-Amino-1MQvsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BFDA-ApprovedVerified14/45 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
5-Amino-1MQ
Tirzepatide
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Tirzepatide
Frequency
Once daily, fasted
—
Lower / starter dose
50 mg / day
—
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
8–12 weeks per cycle
Indefinite for chronic indication
Form
Oral capsule
—
Timing
Morning fasted preferred
Once weekly, any time of day
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Reconstitution
—
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
04Side Effects & Safety
Parameter
5-Amino-1MQ
Tirzepatide
GI symptoms
Mild nausea (anecdotal)
Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Contraindicated
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
5-Amino-1MQ
Tirzepatide
1. Form
Oral capsule. No injection.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Administration
Take with water, fasted preferred.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Morning fasted.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Room temp ≤25 °C, dry place.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Caveat
Monitor B-vitamin status with chronic use.
Pen-supplied. Research vial: 27–31G insulin syringe.